The clinical development of selective alpha-7 nicotinic acetylcholine receptor (α7 nAChR) agonists has hitherto been focused on disorders characterized by cognitive deficits (e.g., Alzheimer’s disease
Video Search
[tubepress output=”searchInput” searchResultsUrl=”https://search.excitingads.com/searchresults/”]
[tubepress enableQuickplay=”true” theme=”tubepress/legacy-quickplay” mode=”tag” tagValue=”SpringerLink” playerLocation=”popup” resultsPerPage=”10″ autoPlay=”false” thumbHeight=”514″ thumbWidth=”625″ responsiveEmbeds=”false” paginationBelow=”false”]
Video Search
[tubepress output=”searchInput” searchResultsUrl=”https://search.excitingads.com/searchresults/”]